Trial reportEuropean heart journal2014
Atrial antitachycardia pacing and managed ventricular pacing in bradycardia patients with paroxysmal or persistent atrial tachyarrhythmias: the MINERVA randomized multicentre international trial.
Trial report in European heart journal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00262119 (MINERVA), which is not on this map. Cited by 49 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
MINERVA: MINimizE Right Ventricular Pacing to Prevent Atrial Fibrillation and Heart Failure
Who cites it
49 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Systematic review and meta-analysis on the impact on outcomes of device algorithms for minimizing right ventricular pacing.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2024Pooled it
- 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.Journal of the American College of Cardiology · 2024Guideline
- Guideline
- 2023 HRS/APHRS/LAHRS guideline on cardiac physiologic pacing for the avoidance and mitigation of heart failure.Heart rhythm · 2023Guideline
- Bias and Loss to Follow-Up in Cardiovascular Randomized Trials: A Systematic Review.Journal of the American Heart Association · 2020Pooled it
- Atrial pacing minimization in sinus node dysfunction and risk of incident atrial fibrillation: a randomized trial.European heart journal · 2023Trial
- Safety and efficiency of ventricular pacing prevention with an AAI-DDD changeover mode in patients with sinus node disease or atrioventricular block: impact on battery longevity-a sub-study of the ANSWER trial.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2016Trial
- Long-term clinical effects of ventricular pacing reduction with a changeover mode to minimize ventricular pacing in a general pacemaker population.European heart journal · 2015Trial
- Electrogram Transition Patterns During Atrial Antitachycardia Pacing-Mediated Termination.Journal of arrhythmia · 2026Article
- Successful Termination of Slow Atrial Tachycardia With 1:1 Atrioventricular Conduction Using a Pacemaker Atrial Antitachycardia Pacing Algorithm.Journal of arrhythmia · 2026Article
- Difference in the efficacy of atrial antitachycardia pacing for suppression of ventricular arrhythmias.Heart rhythm O2 · 2026Article
- Predictive Value of Left Atrial Strain for Atrial High-Rate Episodes in Patients With Permanent Cardiac Pacing.Journal of cardiovascular electrophysiology · 2025Article
- Long-term outcomes of atrial antitachycardia pacing to prevent progression to permanent atrial fibrillation in patients implanted with pacemakers.Heart rhythm O2 · 2025Article
- Cost-effectiveness analyses to assess the value of reactive atrial-based anti-tachycardia pacing for patients with pacemakers and defibrillators: An Australian private healthcare system perspective.Journal of arrhythmia · 2025Article
- European Society of Cardiology (ESC) clinical consensus statement on indications for conduction system pacing, with special contribution of the European Heart Rhythm Association of the ESC and endorsed by the Asia Pacific Heart Rhythm Society, the Canadian Heart Rhythm Society, the Heart Rhythm Society, and the Latin American Heart Rhythm Society.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2025Article
- Physiological Pacing: Historical Review With an Eye to the Future.Journal of cardiovascular electrophysiology · 2025Review
- Do not stop effective atrial-based antitachycardia pacing: Insights into episode duration and success rate for termination.HeartRhythm case reports · 2024Article
- Evaluation of ventricular pacing suppression algorithms in dual chamber pacemaker: Results of "LEADER" study.Journal of arrhythmia · 2024Article
- Pacemaker-induced atrial fibrillation reconsidered-associations with different pacing sites and prevention approaches.Frontiers in cardiovascular medicine · 2024Review
- Comparison of the left ventricular dyssynchrony between stylet-driven and lumen-less lead technique in left bundle branch area pacing using myocardial perfusion scintigraphy.Quantitative imaging in medicine and surgery · 2023Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsAtrial fibrillation (AF) is a common comorbidity in bradycardia patients. Advanced pacemakers feature atrial preventive pacing and atrial antitachycardia pacing (DDDRP) and managed ventricular pacing (MVP), which minimizes unnecessary right ventricular pacing. We evaluated whether DDDRP and MVP might reduce mortality, morbidity, or progression to permanent AF when compared with standard dual-chamber pacing (Control DDDR). METHODS AND
resultsIn a randomized, parallel, single-blind, multi-centre trial we enrolled 1300 patients with bradycardia and previous atrial tachyarrhythmias, in whom a DDDRP pacemaker had recently been implanted. History of permanent AF and third-degree atrioventricular block were exclusion criteria. After a 1-month run-in period, 1166 eligible patients, aged 74 ± 9 years, 50% females, were randomized to Control DDDR, DDDRP + MVP, or MVP. Analysis was intention-to-treat. The primary outcome, i.e. the 2-year incidence of a combined endpoint composed of death, cardiovascular hospitalizations, or permanent AF, occurred in 102/385 (26.5%) Control DDDR patients, in 76/383 (19.8%) DDDRP + MVP patients [hazard ratio (HR) = 0.74, 95% confidence interval 0.55-0.99, P = 0.04 vs. Control DDDR] and in 85/398 (21.4%) MVP patients (HR = 0.89, 95% confidence interval 0.77-1.03, P = 0.125 vs. Control DDDR). When compared with Control DDDR, DDDRP + MVP reduced the risk for AF longer than 1 day (HR = 0.66, 95% CI 0.52-0.85, P < 0.001), AF longer than 7 days (HR = 0.52, 95% CI 0.36-0.73, P < 0.001), and permanent AF (HR = 0.39, 95% CI 0.21-0.75, P = 0.004).
conclusionIn patients with bradycardia and atrial tachyarrhythmias, DDDRP + MVP is superior to standard dual-chamber pacing. The primary endpoint was significantly lowered through the reduction of the progression of atrial tachyarrhythmias to permanent AF. CLINICALTRIALSGOV IDENTIFIER: NCT00262119.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.